产品
编 号：F077612
分子式：C9H12N2O4S
分子量：244.27
分子式：C9H12N2O4S
分子量：244.27
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
400
In-stock
500mg
640
In-stock
结构图
CAS No: 121808-62-6
产品详情
生物活性：
Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al.
体内研究：
In toxicology study in animals, Pidotimod (oral gavage; 800 mg/kg;12 months) is non-toxic in rats and is non-toxic dogs at 600 mg/kg. Pidotimod is non-teratogenic in rats (600 mg/kg orally or 1000 mg/kg IV) and has no effects on subsequent embryofoetal development in rats (up to 1000 mg/kg/day),it has no perinatal or postnatal toxic effects in rats (600 mg/kg orally).In ex vivo experiments in mice, Pidotimod (intraperitoneal administration; 200 mg/kg; 5 days) potentiats natural killer (NK) cell activity and produces an increase in the proliferative response to mitogens such as concanavalin A (ConA) and interleukin-2 (IL-2). Pidotimod (intraperitoneal administration; 10-100 mg/kg) normalizes depletion of peritoneal macrophage numbers, and significantly increases macrophage superoxide anion (O2–) production in methylprednisolone-induced immunosuppressed mice.
Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al.
体内研究：
In toxicology study in animals, Pidotimod (oral gavage; 800 mg/kg;12 months) is non-toxic in rats and is non-toxic dogs at 600 mg/kg. Pidotimod is non-teratogenic in rats (600 mg/kg orally or 1000 mg/kg IV) and has no effects on subsequent embryofoetal development in rats (up to 1000 mg/kg/day),it has no perinatal or postnatal toxic effects in rats (600 mg/kg orally).In ex vivo experiments in mice, Pidotimod (intraperitoneal administration; 200 mg/kg; 5 days) potentiats natural killer (NK) cell activity and produces an increase in the proliferative response to mitogens such as concanavalin A (ConA) and interleukin-2 (IL-2). Pidotimod (intraperitoneal administration; 10-100 mg/kg) normalizes depletion of peritoneal macrophage numbers, and significantly increases macrophage superoxide anion (O2–) production in methylprednisolone-induced immunosuppressed mice.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备